Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023.
Warner J, Bakow B, Brown A, Choe J, Fan E, Ganta T, Glover M, Hadfield M, Hilton C, Khaki A, Kothari S, Lythgoe M, Nagpal S, Nguyen R, Noyd D, Riaz I, Rooney M, Sethi T, Singhi E, Rubinstein S. Characterizing the authorship of phase 3 randomized clinical trials in oncology, 1960-2023. Journal Of Clinical Oncology 2024, 42: 11079-11079. DOI: 10.1200/jco.2024.42.16_suppl.11079.Peer-Reviewed Original ResearchPhase 3 randomized clinical trialPhase 3 RCTsPrimary endpointClinical trialsEligible publicationsProlific authorsSystemic anticancer therapySuccess rateMann-Whitney U testStandard of carePositive publication biasTrial sample sizePositive resultsYear of publicationPublication biasTherapeutic advancesPrimary outcomeAuthorship patternAnticancer therapyExperimental armAuthor's outputMann-WhitneyU testInterquartile rangeAuthor information